the fy21 defense appropriations act provides funding to the department of defense peer reviewed orthopaedic research program (prorp) to support high-impact, clinically-relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 prorp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

applications submitted to the fy21 prorp must address one or more of the following focus areas:

• compartment syndrome: novel treatment strategies to improve current diagnoses for compartment syndrome. alternatives to intracompartmental pressure measurements are encouraged.
• limb stabilization and protection: development of rapid limb stabilization and novel wound protectants for severely or critically wounded limbs to enable prolonged care and eventual transport to the point of definitive treatment.
• osseointegration: identification of best practices to address infection, rejection, and/or failure of percutaneous osseointegrated prosthetic limbs.
• prosthetic and orthotic devices: development of high-performance novel prosthetic or orthotic devices designed to enhance whole person performance and decrease pain in patients with amputation and limb salvage, and impairment. multicenter studies which focus on transfemoral amputees are encouraged.
• retention strategies: development, optimization, and/or validation of battlefield-feasible diagnostic capabilities, decision support tools, interventions, and/or rehabilitation strategies that can facilitate retention on duty for common combat-related musculoskeletal injuries.  biomarker studies are excluded. the current standard of care must be noted. the rehabilitation strategy to be used in the proposed study must be specified, as applicable.
  • battlefield care: strategies that can be utilized at or near the point of injury to allow an injured service member to remain on the battlefield or on mission without the need for evacuation. treatment strategies that allow return to mission effectiveness within 30 days will be considered.
  • return to duty: treatment strategies that can be utilized along the continuum of care and enable return to duty of the service member within one year of injury.
• tissue regeneration therapeutics: development of advanced tissue regeneration therapeutics in nerve, muscle, and/or composite tissue for the restoration of traumatically injured extremities. isolated bone or cartilage tissue engineering studies are excluded. early clinical feasibility studies involving volumetric muscle loss are encouraged.
• translation of early findings: translation of early research findings in the orthopaedic surgical care topic areas listed below to move the research toward clinical trials and clinical practice.
  • soft tissue trauma: strategies to develop and/or identify musculoskeletal extremity soft tissue trauma treatments for shoulder, knee, or chronic ankle instability and sequela only, to optimize return to duty, work, or reintegration.
  • fracture-related infection: strategies to decrease the burden of fracture-related infections (may include prevention, early detection, or improved eradication). alternatives to systemic antibiotic delivery are encouraged. novel approaches that improve the current standard of treatment to prevent fracture-related infections are encouraged. 

https://cdmrp.army.mil/funding/prorp

applied research award – preproposal due may 27, 2021

independent investigators at all academic levels (or equivalent)

supports applied research applications focused on advancing optimal treatment and restoration of function for individuals with musculoskeletal injuries sustained during combat, combat-related activities, and non-battle injuries that impact unit readiness and the ability to return to duty/work.

• proposed research should be supported by preliminary and/or published data and have the potential to make significant advancements toward clinical translation.

• clinical research and clinical trials are not allowed under this award mechanism.

• applications must address one of the following fy21 prorp ara focus areas:

○ limb stabilization and protection

○ retention strategies

− battlefield care

− return to duty

○ osseointegration

• pre-application submission is required; application submission is by invitation only.

the maximum allowable funding for the entire period of performance is $725,000 for total costs.

• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• the maximum period of performance is 3 years.

clinical trial award – preproposal due may 27, 2021

independent investigators at all academic levels (or equivalent) are eligible to submit applications.

•supports rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of military combat-related orthopaedic injuries or non-battle injuries that significantly impact unit readiness and return to duty/work rates.

•investigational new drug or investigational device exemption applications, if needed, should be submitted to the food and drug administration within 6 months of the award date.

•applications must address one of the following fy21 prorp cta focus areas:

○limb stabilization and protection

○retention strategies

−battlefield care

−return to duty

○translation of early findings

−soft tissue trauma

−fracture-related infection

•applications submitted to address the translation of early findings – soft tissue trauma focus area and include the rehabilitation option are eligible for research level 2.

•all applications, regardless of the selected focus area, are eligible for research level 1.

•funding must support a clinical trial and may not be used for animal or preclinical research studies.

•pre-application submission is required; application submission is by invitation only.

research level 1:

•the maximum allowable funding for the entire period of performance is$2.25 million (m) for total costs.

•indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

•the maximum period of performance is 4 years.

research level 2:

•the maximum allowable funding for the entire period of performance is$2.75m for total costs.

•indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

•the maximum period of performance is 4 years.

clinical translational research award – preproposal due may 27, 2021

independent investigators at all academic levels (or equivalent)

•supports high-impact and/or new/emerging clinical research that may or may not be ready for a full-scale randomized controlled clinical trial.

•funding must support clinical research studies involving humans.

•preliminary data relevant to the proposed research project are required.

•investigational new drug or investigational

device exemption applications, if needed, should be submitted to the food and drug administration within 12 months of the award date

•applications must address one of the following fy21 prorp ctra focus areas:

○retention strategies

−battlefield care

−return to duty

○tissue regeneration therapeutics

○compartment syndrome

○osseointegration

○prosthetic and orthotic devices

•pre-application submission is required; application submission is by invitation only.

•the maximum allowable funding for the entire period of performance is$1.5m for total costs.

•indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

•the maximum period of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prorp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the fy21 defense appropriations act is anticipated to provide $8m to the department of defense tscrp to support innovative, high-impact tuberous sclerosis complex (tsc) research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy21 tscrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

applications submitted to the fy21 tscrp are encouraged to address one or more of the following focus areas:

• eradicating tumors associated with tsc and tsc-associated lymphangioleiomyomatosis (lam), including gaining a deeper mechanistic understanding of tsc signaling pathways
• preventing epilepsy, improving treatment, and mitigating neurodevelopmental outcomes associated with tsc-related seizures
• understanding the features of tsc-associated neuropsychiatric disorders (tand) and reducing their impact, including pharmacological and behavioral interventions

https://cdmrp.army.mil/funding/tscrp

exploration – hypothesis development award – letter of intent due june 17, 2021

investigators at all academic levels (or equivalent), including postdoctoral fellows

• supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the tuberous sclerosis complex (tsc) research field.
• projects involving human subjects or human biological substances must be exempt under title 32 of the code of regulations, part 219.104(d) (32 cfr 219.104(d)) or eligible for expedited review under  21 cfr 56.110.
• preliminary data are not required.
• clinical trials are not allowed.
• the maximum allowable funding for the entire period of performance is $150,000 in direct
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 2 years

idea development award – letter of intent due june 17, 2021

established investigators: independent investigators at or above the level of assistant professor (or equivalent);

or

new investigators:  independent investigator at or below the level of assistant professor (or equivalent); or established investigator in an area other than tsc at or above the level of assistant professor seeking to transition to a career in tsc

• promotes ideas that have the potential to yield high-impact findings and new avenues of investigation.
• preliminary data are expected.
• clinical trials are not allowed.
• new investigator option supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition or established investigators from other research fields into career in tsc research.
• applications from new investigators and established investigators will be peer and programmatically reviewed separately.
• the maximum period of funding for the entire period of performance is $500,000 in direct costs
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 3 years

clinical translational research award – letter of intent due june 17, 2021

independent investigators at or above the level of assistant professor (or equivalent)

• supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of tsc.
• applications may include correlative studies that are associated with a completed clinical trial.
• supports studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pk/pd.
• applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.
  • preclinical studies may be appropriate but must include a clinical component.
  • projects that are exploratory and/or strictly animal research will not be considered for funding.
  • clinical translational potential is the most important review criterion.
  • preliminary data are required.
  • the maximum allowable funding for the entire period of performance is $750,000 for direct costs
  • indirect costs may be proposed in accordance with the institution’s negotiated rate agreement
  • the maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions that are available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the tscrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help#@ebrap.org

the fy21 defense appropriations act provides funding to the department of defense prostate cancer research program (pcrp) to support innovative, high-impact prostate cancer research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate, manages the defense health program’s (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 pcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

the mission of the fy21 pcrp is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of service members, veterans, and all the men and their families who are experiencing the impact of the disease.  within this context, the pcrp is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following fy21 pcrp overarching challenges:

• improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer

applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness.  studies should consider both short- and long-term quality of life outcomes.  areas of particular interest include:

• the mental and emotional health of patients and their families/caregivers
• impact of quality of life considerations on decision-making after diagnosis and/or treatment
• identification of vulnerable groups of men and their families at great risk of quality of life detriments
• translation of factors or interventions that improve quality of life outcomes and overall health and wellness
• develop treatments that improve outcomes for men with lethal prostate cancer

applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer and/or biochemical recurrence.  refer to the national comprehensive cancer network guidelines for risk assessment definitions

(https://www.ncc n.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

• advance health equity and reduce disparities in prostate cancer

applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer. 

inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors.

health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients. 

high-risk populations include, but are not limited to, people of african descent (including caribbean), genetically predisposed populations, service members, and veterans.

underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities.

• define the biology of lethal prostate cancer to reduce death

applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence.  refer to the national comprehensive cancer network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

idea development award – letter of intent due september 2, 2021

established investigators:  independent investigators at all levels

new investigators:  investigators that meet the following criteria at the application submission deadline date:

• have the freedom to pursue individual aims without formal mentorship
• have not previously received a pcrp idea development award and/or health disparity research award
  • have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of terminal degree (excluding residency or family medical leave)
• supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the fy21 pcrp overarching challenges.
• emphasis is equally placed on innovation and impact.
• preliminary data are encouraged, but not required.
• clinical trials are not allowed.
• each pi may submit only one application.
• multidisciplinary projects are encouraged, and multi-institutional projects are allowed.
• must address at least one of the fy21 pcrp overarching challenges.
• the maximum allowable funding for the entire period of performance is $750,000 for direct costs.
• the maximum period of performance is 3 years.

the fy21 defense appropriations act provides funding to the department of defense prostate cancer research program (pcrp) to support innovative, high-impact prostate cancer research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate, manages the defense health program’s (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 pcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

the mission of the fy21 pcrp is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of service members, veterans, and all the men and their families who are experiencing the impact of the disease.  within this context, the pcrp is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following fy21 pcrp overarching challenges:

• improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer

applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness.  studies should consider both short- and long-term quality of life outcomes.  areas of particular interest include:

• the mental and emotional health of patients and their families/caregivers
• impact of quality of life considerations on decision-making after diagnosis and/or treatment
• identification of vulnerable groups of men and their families at great risk of quality of life detriments
• translation of factors or interventions that improve quality of life outcomes and overall health and wellness
• develop treatments that improve outcomes for men with lethal prostate cancer

applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer and/or biochemical recurrence.  refer to the national comprehensive cancer network guidelines for risk assessment definitions

(https://www.ncc n.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

• advance health equity and reduce disparities in prostate cancer

applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer. 

inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors.

health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients. 

high-risk populations include, but are not limited to, people of african descent (including caribbean), genetically predisposed populations, service members, and veterans.

underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities.

• define the biology of lethal prostate cancer to reduce death

applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence.  refer to the national comprehensive cancer network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

translational science award – letter of intent due july 15, 2021

independent investigators at all levels

• supports advanced translational research that will foster transformation of promising ideas in prostate cancer into clinical applications, ultimately providing a solution to one or more of the fy21 pcrp overarching challenges.
• translational research may be defined as an integration of basic science and clinical observations, including a reciprocal flow of ideas and information from bench to beside and/or bedside to bench.
• supports a broad range of translational studies such as:

○    advanced translation of results from animal studies to applications with human samples/cohorts 

○    late-stage preclinical work leading to/preparing for a clinical trial, e.g., investigational new drug application submission

○    correlative studies that are associated with an open/ongoing or completed clinical trial, e.g., projects that utilize biospecimens from clinical trial to improve clinical management of prostate cancer and/or define new areas of research

○    projects that develop endpoints for clinical trials

• preliminary data to support the scientific rationale and feasibility of the research approaches are required.  the inclusion of additional preliminary data to support the clinical relevance of the idea is strongly encouraged.
• ·      clinical trials are not allowed.
  • each pi may submit only one application.
  • partnering pi option:  allows two pis, termed initiating and partnering pis, to collaborate on a single application.  collaborations between basic science and clinical researchers are highly encouraged.
  • must address at least one of the fy21 pcrp overarching challenges.
• the maximum allowable funding for the entire period of performance is $750,000 for direct costs.
• the maximum period of performance is 3 years.

health disparity research award – letter of intent due july 15, 2021

established investigators:  independent investigators at all levels

new investigators:  investigators that meet the following criteria at the application submission deadline date:

• have the freedom to pursue individual aims without formal mentorship
• have not previously received a pcrp health disparity research award and/or idea development award
• have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of a terminal degree (excluding residency or family medical leave)
• supports research ideas that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality.
• proposed projects must address one of the following health disparity focus areas:  (1) biological contributors, (2) environmental factors, (3) social and cultural factors, or (4) access to healthcare.
• proposed projects may include basic, translational, or clinical research, including clinical trials.
• primary emphasis will be placed on the potential impact of the proposed work.
• preliminary data are encouraged, but not required.
• each pi may submit only one application.
• must address at least one of the fy21 pcrp overarching challenges.
• the maximum allowable funding for the entire period of performance is $750,000 for direct costs.
• the maximum period of performance is 3 years

the fy21 defense appropriations act provides funding to the department of defense prostate cancer research program (pcrp) to support innovative, high-impact prostate cancer research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate, manages the defense health program’s (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 pcrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

the mission of the fy21 pcrp is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of service members, veterans, and all the men and their families who are experiencing the impact of the disease.  within this context, the pcrp is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following fy21 pcrp overarching challenges:

• improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer

applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness.  studies should consider both short- and long-term quality of life outcomes.  areas of particular interest include:

• the mental and emotional health of patients and their families/caregivers
• impact of quality of life considerations on decision-making after diagnosis and/or treatment
• identification of vulnerable groups of men and their families at great risk of quality of life detriments
• translation of factors or interventions that improve quality of life outcomes and overall health and wellness
• develop treatments that improve outcomes for men with lethal prostate cancer

applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer and/or biochemical recurrence.  refer to the national comprehensive cancer network guidelines for risk assessment definitions

(https://www.ncc n.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

• advance health equity and reduce disparities in prostate cancer

applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer. 

inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors.

health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients. 

high-risk populations include, but are not limited to, people of african descent (including caribbean), genetically predisposed populations, service members, and veterans.

underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities.

• define the biology of lethal prostate cancer to reduce death

applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence.  refer to the national comprehensive cancer network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

https://cdmrp.army.mil/funding/pcrp

early investigator research award – letter of intent due june 17, 2021

by march 31, 2022

postdoctoral principal investigators (pis):

• must possess a doctoral degree (or equivalent)
• have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training)
• supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.
• pis must have a designated mentor who is an experienced prostate cancer researcher.
• must include a researcher development plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the pi’s career development.

must address at least one of the fy21 pcrp overarching challenges.

• the maximum allowable funding for the entire period of performance is $300,000 for direct costs.
• the maximum period of performance is 2 years.

physician research award – letter of intent due june 17, 2021

at the time of application submission, the pi must be either:

• in the last year of an accredited medical residency or medical fellowship program

or

within 5 years of having initiated a faculty appointment (including instructor positions)

• supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.
• pis must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.
• pis must have a designated mentor with an established research program in prostate cancer.
• applications are strongly encouraged to demonstrate protection of at least 40% of the pi’s time for prostate cancer research (not required to be exclusive to this award). 
• must include a researcher development plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the pi’s career development.
• must address at least one of the fy21 pcrp overarching challenges.
• the maximum allowable funding for the entire period of performance is $750,000 for direct costs.
• the maximum period of performance is 4 years

the harrington scholar-innovator award recognizes physician-scientist innovators throughout the us and canada, whose research has the potential to change standard of care. the scholar-innovator award provides research and drug development support to help bridge the gap between basic discovery and the clinical realm.

up to twelve harrington scholar-innovator awards are made each year through a competitive selection process.

together with the quebec consortium for drug discovery (cqdm), brain canada is pleased to share an upcoming funding opportunity for canadian researchers. cqdm’s quantum leap pharma-led funding program for drug discovery research aims to support innovative translational biopharmaceutical research projects that have the potential to improve, facilitate and/or accelerate the drug discovery process and the development of safer and more effective drugs.

projects selected as part of the quantum leap program focus on developing cutting-edge technologies with the potential to significantly advance the r&d activities of cqdm’s pharmaceutical members. quantum leap projects are executed in close collaboration and with the expert support and funds of pharmaceutical members.

brain canada is partnering with the quantum leap pharma-led funding program for drug discovery research on eligible brain related projects.

please note: budget structures can vary depending on each project, please contact cqdm to confirm eligibility before applying,

the cmhc award for northern or remote research is a bursary of up to $5,000.

it allows people doing housing research or fieldwork to undertake engagement and consultations activities (including travel) in northern or remote areas of canada. the field of research must be in one of the national housing strategy’s priority areas.

the goal is to build knowledge and fill research gaps on northern or remote housing.

if this award is of interest, please contact dr. batia stolar, associate vice-president, research & graduate studies, at avp.research@lakeheadu.ca for more information.

the fy21 defense appropriations act provides funding to the department of defense spinal cord injury research program (scirp) to support innovative, high-impact spinal cord injury (sci) research¹. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 scirp program announcements and general application instructions for the following award mechanisms will be posted on the grants.gov website. 

applications submitted to the fy21 scirp must address one or more of the following focus areas*:

• psychosocial issues relevant to people with sci, their families, and/or their care-partners
• preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes
• identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of  treatment efficacies
• bowel, genitourinary, cardiopulmonary dysfunction, and neuropathic pain
• rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing neuroplasticity and recovery to improve function after sci

https://cdmrp.army.mil/funding/scirp

clinical trial award – preproposal due may 24, 2021

principal investigator (pi): investigators at all academic levels (or equivalent).

*new for fy21*

optional partnering investigator: an independent, early- career investigator within 10 years after completion of terminal degree

• preproposal is required; application submission is by invitation only.
• fund phase 0, 1, or 2 clinical trials with the potential to have a major impact on treatment or management of spinal cord injury (sci) and its consequences.
• alternative study designs to traditional randomized clinical trials are allowed but should be appropriate to the objective of the trial.
• applications must include at least two individuals with lived sci experience as members of the research team.
• preclinical data required for all clinical trial applications.
• *new* early-career partnering pi option
• the maximum allowable funding for the entire period of performance is  $3 million (m) for direct costs.
• the maximum period of performance is 4 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions e available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the scirp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil/scirp).

*detailed fy21 scirp focus areas

applications submitted to the fy21 scirp must address one or more of the following focus areas:

• *updated fy21* psychosocial issues relevant to people with sci, their families, and/or their care-partners:

o   applications should directly address, or show clear relevance to, the needs of service members and veterans.

o   projects should provide an understanding of critical factors promoting psychosocial wellbeing, leading to implementation of potential treatments and interventions.

o   studies addressing social isolation, loneliness, depression as well as resilience, self-efficacy, and interactions between people living with sci and their care-partners are especially encouraged. 

o   preclinical animal studies are not responsive to this focus area.

• preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes:

o   responsive projects may include surgical and acute care management of sci.

o   therapeutics (devices and pharmacologic interventions) to stabilize sci in the pre-hospital environment and during transport are encouraged.

o   applications proposing neuroprotective interventions need to demonstrate a clinically feasible window for treatment and more than an incremental improvement over existing therapies.

• identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of treatment efficacies:

o   biomarkers must focus on diagnosis, prognosis, progression, and/or recovery of sci.

o   projects with a clear link between a biomarker and underlying physiology are encouraged.  projects can include imaging and other modalities.

o   applications should demonstrate a clear path to clinical use.

o   biomarker studies directed at identifying the best single or combination of treatments for individuals (personalized medicine) are encouraged.

• bowel, genitourinary, cardiopulmonary dysfunction, and neuropathic pain:

o   studies of the mechanisms of dysfunction and neuropathic pain specific to sci must demonstrate a clear path from increased understanding to advancing treatments.

o   studies addressing the needs of and treatments for individuals with sci across the full lifespan from acute to chronic injury are encouraged.

• rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing neuroplasticity and recovery to improve function after sci:

o   studies that address critical questions of dosing, targeting, or safety required to move the research toward clinical use are supported.

o   applications studying mechanisms of regeneration or identifying novel therapeutic targets must include a feasible projected pathway for translation and clinical implementation.

o   basic research projects designed to understand general mechanisms underlying axonal sprouting, regeneration, or neuroplasticity are discouraged unless they directly address translatable approaches.

point of contact:

cdmrp help desk

301-682-5507

usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

¹ funding is provided through the fy21 appropriation for peer-reviewed spinal cord research

the fy21 defense appropriations act provides funding to the department of defense spinal cord injury research program (scirp) to support innovative, high-impact spinal cord injury (sci) research¹. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 scirp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

applications submitted to the fy21 scirp must address one or more of the following focus areas*:

• psychosocial issues relevant to people with sci, their families, and/or their care-partners
• preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes
• identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of  treatment efficacies
• bowel, genitourinary, cardiopulmonary dysfunction, and neuropathic pain
• rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing neuroplasticity and recovery to improve function after sci

https://cdmrp.army.mil/funding/scirp

clinical trial award – preproposal due may 24, 2021

principal investigator (pi): investigators at all academic levels (or equivalent).

*new for fy21*

optional partnering investigator: an independent, early-career investigator within 10 years after completion of terminal degree

• preproposal is required; application submission is by invitation only.
  • fund phase 0, 1, or 2 clinical trials with the potential to have a major impact on treatment or management of spinal cord injury (sci) and its consequences.
  • alternative study designs to traditional randomized clinical trials are allowed but should be appropriate to the objective of the trial.
  • applications must include at least two individuals with lived sci experience as members of the research team.
• preclinical data required for all clinical trial applications.
• *new* early-career partnering pi option
• the maximum allowable funding for the entire period of performance is $3 million (m) for direct costs.
• the maximum period of performance is 4 years.

translational research award – preproposal due may 24, 2021

principal investigator: investigators at all academic levels (or equivalent).

*new for fy21*

optional partnering investigator: an independent, early-career investigator within 10 years after completion of terminal degree

• preproposal is required; application submission is by invitation only.
• fund studies that accelerate the movement of promising ideas in sci research into clinical applications.
• applications must include at least one individual with lived sci experience as a member of the research team.
• preliminary data required.
• the scirp translational research award may include a pilot clinical trial as part of the proposed research where limited clinical testing of a novel intervention or device is necessary to inform the next step in the continuum of translational research.
• *new* early-career partnering pi option
• the maximum allowable funding for the entire period of performance is $1.25 m for direct costs.
• the maximum period of performance is 3 years.

investigator-initiated research award – preproposal due may 24, 2021

principal investigator: investigators at all academic levels (or equivalent).

*new for fy21*

optional partnering investigator: an independent, early-career investigator within 10 years after completion of terminal degree

• preproposal is required; application submission is by invitation only.
• fund sci-related research that has the potential to make an important contribution to sci research, patient care, and/or quality of life.
• studies focused exclusively on target identification are discouraged.
• preliminary data required.
• clinical trials are not allowed.
• *new* early-career partnering pi option
• the maximum allowable funding for the entire period of performance is $500,000 for direct costs.
• the maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions are available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the scirp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil/scirp).

*detailed fy21 scirp focus areas

applications submitted to the fy21 scirp must address one or more of the following focus areas:

• *updated fy21* psychosocial issues relevant to people with sci, their families, and/or their care-partners:

o    applications should directly address, or show clear relevance to, the needs of service members and veterans.

o    projects should provide an understanding of critical factors promoting psychosocial wellbeing, leading to implementation of potential treatments and interventions.

o    studies addressing social isolation, loneliness, depression as well as resilience, self-efficacy, and interactions between people living with sci and their care-partners are especially encouraged. 

o    preclinical animal studies are not responsive to this focus area.

• preserving and protecting spinal cord tissue at time of injury for improved neurologic outcomes:

o    responsive projects may include surgical and acute care management of sci.

o    therapeutics (devices and pharmacologic interventions) to stabilize sci in the pre-hospital environment and during transport are encouraged.

o    applications proposing neuroprotective interventions need to demonstrate a clinically feasible window for treatment and more than an incremental improvement over existing therapies.

• identifying and validating biomarkers for diagnosis, prognosis, and for evaluation of treatment efficacies:

o    biomarkers must focus on diagnosis, prognosis, progression, and/or recovery of sci.

o    projects with a clear link between a biomarker and underlying physiology are encouraged.  projects can include imaging and other modalities.

o    applications should demonstrate a clear path to clinical use.

o    biomarker studies directed at identifying the best single or combination of treatments for individuals (personalized medicine) are encouraged.

• bowel, genitourinary, cardiopulmonary dysfunction, and neuropathic pain:

o    studies of the mechanisms of dysfunction and neuropathic pain specific to sci must demonstrate a clear path from increased understanding to advancing treatments.

o    studies addressing the needs of and treatments for individuals with sci across the full lifespan from acute to chronic injury are encouraged.

• rehabilitation and regeneration—maximizing the function of the residual neural circuitry, including harnessing neuroplasticity and recovery to improve function after sci:

o    studies that address critical questions of dosing, targeting, or safety required to move the research toward clinical use are supported.

o    applications studying mechanisms of regeneration or identifying novel therapeutic targets must include a feasible projected pathway for translation and clinical implementation.

o    basic research projects designed to understand general mechanisms underlying axonal sprouting, regeneration, or neuroplasticity are discouraged unless they directly address translatable approaches.

point of contact:

cdmrp help desk

301-682-5507

help@ebrap.org

¹ funding is provided through the fy21 appropriation for peer-reviewed spinal cord research